F
Fernando C. Maluf
Researcher at University of São Paulo
Publications - 69
Citations - 1279
Fernando C. Maluf is an academic researcher from University of São Paulo. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 10, co-authored 47 publications receiving 831 citations.
Papers
More filters
Journal ArticleDOI
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Silke Gillessen,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Alberto Bossi,Robert G. Bristow,Brett S. Carver,Daniel Castellano,Byung Ha Chung,Noel W. Clarke,Gedske Daugaard,Ian D. Davis,Johann S. de Bono,Rodolfo Borges dos Reis,Charles G. Drake,Ros Eeles,Eleni Efstathiou,Christopher P. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Martin E. Gleave,Susan Halabi,Axel Heidenreich,Celestia S. Higano,Nicolas James,Philip W. Kantoff,Pirkko-Liisa Kellokumpu-Lehtinen,Raja B. Khauli,Gero Kramer,Chris Logothetis,Fernando C. Maluf,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Vedang Murthy,William Oh,Piet Ost,Anwar R. Padhani,Chris Parker,Colin C. Pritchard,Mack Roach,Mark A. Rubin,Charles J. Ryan,Fred Saad,Oliver Sartor,Howard I. Scher,Avishay Sella,Neal D. Shore,Matthew R. Smith,Howard R. Soule,Cora N. Sternberg,Hiroyoshi Suzuki,Christopher Sweeney,Matthew R. Sydes,Ian F. Tannock,Bertrand Tombal,Riccardo Valdagni,Thomas Wiegel,Aurelius Omlin +60 more
TL;DR: The presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available.
Journal ArticleDOI
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]
Silke Gillessen,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Anders Bjartell,Alberto Bossi,Alberto Briganti,Robert G. Bristow,Kim N. Chi,Noel W. Clarke,Ian D. Davis,Johann S. de Bono,Charles G. Drake,Ignacio Duran,Ros Eeles,Eleni Efstathiou,Christopher P. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Martin E. Gleave,Susan Halabi,Axel Heidenreich,Axel Heidenreich,Daniel Heinrich,Celestia S. Higano,Celestia S. Higano,Michael S Hofman,Michael S Hofman,Maha Hussain,Nicolas James,Ravindran Kanesvaran,Philip W. Kantoff,Philip W. Kantoff,Raja B. Khauli,Raya Leibowitz,Chris Logothetis,Chris Logothetis,Fernando C. Maluf,Robin Millman,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Hind Mrabti,Declan G. Murphy,Declan G. Murphy,Vedang Murthy,William Oh,Piet Ost,Joe M. O'Sullivan,Joe M. O'Sullivan,Anwar R. Padhani,Chris Parker,Darren M.C. Poon,Colin C. Pritchard,Robert E. Reiter,Mack Roach,Mark A. Rubin,Charles J. Ryan,Fred Saad,Juan Pablo Sade,Oliver Sartor,Howard I. Scher,Howard I. Scher,Neal D. Shore,Eric J. Small,Matthew R. Smith,Howard R. Soule,Cora N. Sternberg,Thomas Steuber,Hiroyoshi Suzuki,Christopher Sweeney,Matthew R. Sydes,Mary-Ellen Taplin,Bertrand Tombal,Levent Türkeri,Inge M. van Oort,Almudena Zapatero,Aurelius Omlin,Aurelius Omlin +80 more
TL;DR: These voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse and provide a practical guide to help clinicians discuss therapeutic options with patients.
Journal ArticleDOI
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.
Raphael Brandao Moreira,Marcio Debiasi,Edoardo Francini,Pier Vitale Nuzzo,Pier Vitale Nuzzo,Guillermo de Velasco,Fernando C. Maluf,Andre P. Fay,Joaquim Bellmunt,Toni K. Choueiri,Fabio A.B. Schutz +10 more
TL;DR: A meta-analysis of randomized controlled trials for mCRPC patients found that abiraterone was associated with an increased risk of cardiovascular events, while enzalutamide wasassociated with an increase risk of fatigue.
Journal ArticleDOI
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Sabine Schmid,Sabine Schmid,Aurelius Omlin,Celestia S. Higano,Christopher Sweeney,Nieves Martinez Chanza,Niven Mehra,Malou C.P. Kuppen,Malou C.P. Kuppen,Himisha Beltran,Himisha Beltran,Vincenza Conteduca,Daniel Vargas Pivato de Almeida,Fernando C. Maluf,William Oh,Che-Kai Tsao,Oliver Sartor,Elisa Ledet,Giuseppe Di Lorenzo,Steven Yip,Kim N. Chi,Diletta Bianchini,Ugo De Giorgi,Aaron R. Hansen,Tomasz M. Beer,Pernelle Lavaud,Rafael Morales-Barrera,Marcello Tucci,Elena Castro,Kostas Karalis,Andries M. Bergman,Mo Linh Le,Ursina Zürrer-Härdi,Carmel Pezaro,Hiroyoshi Suzuki,Andrea Zivi,Dirk Klingbiel,Sämi Schär,Silke Gillessen +38 more
TL;DR: In a case series of 508 patients, platinum-based therapy was associated with antitumor activity, especially among patients with known DNA repair gene aberrations.
Journal ArticleDOI
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Silke Gillessen,Andrew J. Armstrong,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Anders Bjartell,Alberto Bossi,Alberto Briganti,Robert G. Bristow,Muhammad Bulbul,Orazio Caffo,Kim N. Chi,Caroline S. Clarke,Noel W. Clarke,Ian D. Davis,Johann S. de Bono,Ignacio Duran,Rosalind A. Eeles,Eleni Efstathiou,Jason A. Efstathiou,O. Ekeke,Christopher H. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Daniel J. George,Martin E. Gleave,Susan Halabi,D. Heinrich,C. Higano,Michael S Hofman,Maha Hussain,Nicholas D. James,Robert Jones,Ravindran Kanesvaran,Raja B. Khauli,Laurence Klotz,Raya Leibowitz,Christopher J. Logothetis,Fernando C. Maluf,Robin Millman,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Hind Mrabti,Declan G. Murphy,Vedang Murthy,William Oh,Piet Ost,Joe M. O'Sullivan,Anwar R. Padhani,Chris Parker,Darren M.C. Poon,Colin C. Pritchard,Danny M. Rabah,Dana E. Rathkopf,Robert E. Reiter,M.L. Rubin,Charles J. Ryan,Fred Saad,Juan Pablo Sade,Oliver Sartor,Howard I. Scher,Neal D. Shore,Iwona Skoneczna,Eric J. Small,Matthew R. Smith,Howard R. Soule,Daniel E. Spratt,Cora N. Sternberg,H. Suzuki,Christopher Sweeney,Matthew R. Sydes,Mary-Ellen Taplin,Derya Tilki,Bertrand Tombal,Levent Türkeri,Hiroji Uemura,Hirotsugu Uemura,Inge M. van Oort,Kosj Yamoah,Dingwei Ye,Almudena Zapatero,Aurelius Omlin +84 more
TL;DR: The 2019 Advanced Prostate Cancer Consensus Conference (APCCC) as mentioned in this paper addressed three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood.